ARS Pharmaceuticals Intangible Assets

ARS Pharmaceuticals (SPRY) currently reports a intangible assets of $14M as of March 2026. That compares with $7.2M in the prior-year period — up 95.8% year over year. Use the charts on this page to explore ARS Pharmaceuticals's intangible assets history and peer comparisons.

ARS Pharmaceuticals's intangible assets increased from $7.2M to $14M — a 95.8% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ARS Pharmaceuticals reported $14M in intangible assets as of March 2026. That compares with $7.2M in the prior-year period — up 95.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $14M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for ARS Pharmaceuticals, and consider following SPRY for alerts when major investors trade the stock.

ARS Pharmaceuticals is classified in the Healthcare sector. On intangible assets, it currently shows $14M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SPRY with unrelated industries.